Diagnostics require precision and predictive ability to be clinically useful. Integration of multi-
omic with clinical data is crucial to our understanding of disease pathogenesis and …

The majority of breast cancers are oestrogen receptor-positive (ER+). In ER+ cancers,
oestrogen acts as a disease driver, so these tumours are likely to be susceptible to …

Context.—The Oncotype DX recurrence score (RS) is a widely used test that provides
prognostic information on the likelihood of disease recurrence and predictive information on …

Methods A decision tree categorized hypothetical patients with HR+/HER2− early-stage
invasive breast cancer according to clinical and genomic risk, and integrated clinical expert …

Abstract Background and objectives The Oncotype DX Breast Recurrence Score test is used
to estimate distant recurrence risk of hormone receptor-positive (HR+) and human epidermal …

Introduction Chemotherapy (CT) is commonly used as an adjuvant treatment for women with
early breast cancer (BC). However, not all patients benefit from CT, while all are exposed to …

Background and Objectives The 21-gene assay (the Oncotype DX Breast Recurrence
Score® test) estimates the 10-year risk of distant recurrence in hormone receptor positive …

Background Patients with early-stage hormone receptor positive, human epidermal growth
factor receptor-2 (HER2) negative invasive breast cancer with 1–3 positive lymph nodes …

Genomic analysis through various platforms is an essential tool for determining prognosis
and treatment in a significant subgroup of early-stage breast cancer patients with hormone …

Objective The purpose of this study was to determine whether breast cancer patients at
stage T2N0 with tumor size≥ 4 cm and< 4 cm. Method Patients with T2N0 stage breast …